Isradipine

Isradipine is a dihydropyridine calcium channel blocker used for the treatment of hypertension. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class.

Chemical structure of Isradipine
Mechanism
Curator reviewed
Primary indication
For the management of mild to moderate essential hypertension.Curator reviewed · 1 structured indication
Formula / weight
C19H21N3O5 · 371.3871 g/mol (avg)
First approval
United States, 1998

Resolves to

Structure
InChIKeyHMJIYCCIJYRONP-UHFFFAOYSA-NSMILESCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
Transporters

What you can answer from here — as of September 23, 2026

8Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
2,218Drug interactionsStructured to mechanism, not free text
Sign in
13Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
40Marketed productsAcross 4 countries and 17 labellers
Sign in
1ATC codeIncluding every combination product, plus 30 drug categories
Sign in
23+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Isradipine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account